6 Times Animal Testing Failed—and Human Science Got It Right
For decades, animal experimentation has been treated as a necessity of biomedical research. But when it comes to predicting what actually happens in the human body, it fails time and time again.
Here are six examples that show the reality: Human-based science avoids animal suffering and produces better, more reliable results for people.
1. Organ-Chips Replicate Human Biology More Accurately Than Animals
Microfluidic organ-chips—tiny devices lined with living human cells—can mimic the function of organs like the lung, liver, and intestine.
Unlike animal models, these systems:
- Recreate human-specific physiology,
- Simulate real organ-level responses, and
- Allow researchers to observe disease and drug effects in real time.
As organ-chips developers at Emulate note, these platforms “more faithfully model human biology” than conventional approaches like animal models.
The closer a model gets to actual human biology, the more predictive it becomes—and nonhuman animals aren’t that model.
2. Liver-Chips Outperform Animal Testing in Predicting Drug Toxicity
Drug-induced liver injury is one of the leading reasons medications fail—often after animal testing suggests they’re safe.
For example, according to an analysis published in Communications Medicine in 2022, “failure is common because the models used preclinically—which include computational, traditional cell culture, and animal models—have limited predictive validity.”
Human liver-on-a-chip technology is changing that.
Researchers found that liver-chips correctly identified ~87% of drugs known to cause liver injury in humans, significantly outperforming traditional animal models. These microengineered systems replicate human liver structure and function in ways other animals can’t.
Animal biology doesn’t reliably predict human drug toxicity. Human-relevant systems can.
3. The TGN1412 Disaster: Animal Tests Missed a Life-Threatening Reaction
In 2006, the drug TGN1412 was tested on animals and deemed safe. Then came human trials.
Healthy human volunteers experienced a catastrophic immune reaction “signaling a failure of preclinical testing.”
An analysis by Husain Attarwala in The Journal of Young Pharmacists gives more details: “After [the] very first infusion of a dose 500 times smaller than that found safe in animal studies, all six human volunteers faced life-threatening conditions involving multiorgan failure.”
Preclinical animal testing didn’t predict this drug’s devastating effects. But afterward, scientists used human immune cell assays and successfully reproduced the same dangerous response in the lab.
Animal models missed a life-threatening reaction for people. Human-based research would’ve caught it before any one of them was harmed.
4. Monoclonal Antibodies Expose the Limits of Animal Models
Monoclonal antibody (mAb) therapies are treatments designed to interact with highly specific human targets, often at the molecular level, to help the immune system fight disease.
This specificity creates a problem: those targets frequently don’t exist—or don’t behave the same way—in different species. As a result, mAb animal studies can fail to detect immune reactions, toxicity, and therapeutic effectiveness for people.
That’s why researchers increasingly rely on human immune cell assays for biologics (especially after failures like TGN1412).
On April 10, 2026, the U.S. Food & Drug Administration (FDA) announced a new initiative to replace animal testing in the development of mAb therapeutics and other drugs in animal models with “more effective, human-relevant methods.”
When treatments are designed for human biology, testing them in other species becomes scientifically unreliable.
5. COVID-19 Brain Organoids Revealed What Animal Models Couldn’t
During the COVID-19 pandemic, researchers used human brain organoids to study infection. These miniature, lab-grown human-based brain models showed that SARS-CoV-2 could infect brain cells, damage blood vessels, and contribute to neurological symptoms patients endured.
Animal models struggled to replicate these human-specific neurological effects.
In a 2023 study, the authors acknowledge “[n]one of the currently available animal models fully replicates PCC [post-COVID-19 conditions] in humans.”
Human organoids provided direct insight into how the virus affects the human brain—something animal experiments couldn’t fully capture.
6. In Drug Development, Animal Testing Overwhelmingly Fails
More than 9 out of 10 drugs that succeed in animal testing fail in humans. Per a 2023 review in ATLA, “the majority of these failures are due to […] safety issues revealed in human trials that were not apparent in animal tests.”
Indeed, over 92% of the time, animal models fail to predict how human bodies will respond. These nonhuman models harm and kill animals, cost time, waste money, and delay therapies that will actually help people.
Finally policymakers are starting to acknowledge these failures.
In 2022, Congress passed the FDA Modernization Act 2.0, removing the administration’s requirement for animal testing in drug development. This law has opened the door to human-relevant methods in U.S. drug development.
And last December, the FDA Modernization Act 3.0 passed the U.S. Senate unanimously, pushing the FDA to align its regulations with modern science and expand the use of non-animal, human-relevant approaches.
Lawmakers are now acting on what the data makes obvious: human-based research performs better than animal tests.
The Future of Science Is Clear
Animal models miss critical human outcomes. Human-based methods predict them more accurately.
If the goal of research is to understand and treat human disease, the most reliable model is the human body itself.
Your Call to Action: The FDA Modernization Act 3.0 is one step closer to becoming law. Urge your representatives to keep that momentum going and help accelerate the transition to research that reflects human biology and frees animals from labs.